Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
RDHL RedHill Biopharma Ltd. daily Stock Chart
RDHL [NASD]
RedHill Biopharma Ltd.
Healthcare | Biotechnology | Israel
financial highlights | statements
Index- P/E- EPS (ttm)-2.46 Insider Own8.53% Shs Outstand171.64M Perf Week-3.22%
Market Cap1.55B Forward P/E- EPS next Y-0.54 Insider Trans0.00% Shs Float15.52M Perf Month2.85%
Income- PEG- EPS next Q-0.63 Inst Own10.93% Short Float1.28% Perf Quarter0.11%
Sales0.58M P/S2652.62 EPS this Y-3.90% Inst Trans-14.77% Short Ratio2.01 Perf Half Y-8.53%
Book/sh2.84 P/B3.17 EPS next Y77.40% ROA- Target Price26.50 Perf Year-33.41%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range8.16 - 14.22 Perf YTD-13.86%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.64% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low10.42% ATR0.52
Employees8 Current Ratio- Sales Q/Q48200.00% Oper. Margin- RSI (14)46.02 Volatility4.11% 5.73%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.26 Prev Close9.06
ShortableYes LT Debt/Eq- EarningsNov 13 BMO Payout- Avg Volume99.13K Price9.01
Recom2.00 SMA20-4.44% SMA500.96% SMA200-5.22% Volume124,825 Change-0.55%
Oct-06-17Initiated Seaport Global Securities Buy $19
Oct-04-17Reiterated H.C. Wainwright Buy $33 → $36
Feb-24-17Reiterated FBR & Co. Outperform $36 → $25
Jul-27-16Reiterated FBR Capital Outperform $33 → $36
Sep-29-15Initiated Nomura Buy
Jul-29-15Reiterated ROTH Capital Buy $30 → $31
Jun-17-15Reiterated H.C. Wainwright Buy $23 → $32
Jun-15-15Reiterated ROTH Capital Buy $27.50 → $30
Oct-10-17 06:10AM  RedHill Biopharma to Present at the BioNetwork 2017 Partnering Summit GlobeNewswire
Oct-03-17 07:41AM  RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) GlobeNewswire -13.14%
07:00AM  RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) GlobeNewswire
Oct-02-17 08:30PM  RedHill Biopharma Ltd (RDHL): How Does It Impact Your Portfolio? Simply Wall St.
07:00AM  RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohns Disease with Top-Line Results Expected Mid-2018 GlobeNewswire
Sep-28-17 07:00AM  RedHill Biopharma to Announce Top-Line Results from BEKINDA® 12 mg Phase II Study for IBS-D on October 3rd, 2017 GlobeNewswire +10.56%
Sep-18-17 08:00AM  RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering its Combination Therapy for Hard-to-Treat Cancers GlobeNewswire
07:00AM  RedHill Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-15-17 12:01PM  Is RedHill Biopharma Ltd (RDHL) Undervalued? Simply Wall St.
Sep-13-17 07:01AM  RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S. GlobeNewswire
Sep-07-17 08:00AM  RedHill Biopharma to Present at the 10th Annual BioPharm America International Partnering Conference GlobeNewswire
Aug-31-17 07:00AM  RedHill Biopharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-17-17 02:55PM  RedHill keen on growth makes another commercial play American City Business Journals
07:01AM  RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules GlobeNewswire
Aug-10-17 08:01AM  RedHill Biopharma Provides 2017 Semi-Annual Business Update GlobeNewswire
Jul-31-17 08:02AM  RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn's Disease GlobeNewswire
Jul-27-17 11:51AM  RedHill Biopharma Ltd. :RDHL-US: Earnings Analysis: Q2, 2017 By the Numbers : July 27, 2017 Capital Cube -5.17%
07:00AM  Corporate News Blog - FDA Grants Fast Track Designation to Flex Pharmas FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS ACCESSWIRE
Jul-25-17 01:40PM  RedHill Biopharma reports initial revenues in Q2 as it grows Raleigh ops American City Business Journals +7.58%
07:22AM  RedHill Biopharma Reports 2017 Second Quarter Financial Results GlobeNewswire
07:00AM  RedHill Biopharma Reports 2017 Second Quarter Financial Results GlobeNewswire
Jul-18-17 07:00AM  RedHill Biopharma to Host Second Quarter 2017 Financial Results Conference Call on July 25, 2017 GlobeNewswire
Jul-17-17 08:01AM  RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D GlobeNewswire
Jul-12-17 08:01AM  RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn's Disease GlobeNewswire
Jun-19-17 06:00AM  RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis GlobeNewswire +5.58%
Jun-15-17 08:01AM  RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA(TM)) for H. pylori Infection GlobeNewswire
08:00AM  RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA) for H. pylori Infection GlobeNewswire
Jun-14-17 08:01AM  RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis GlobeNewswire
Jun-13-17 08:02AM  RedHill Biopharma Initiates Promotion of Donnatal® and EnteraGam® in the U.S. GlobeNewswire
08:00AM  RedHill Biopharma Initiates Promotion of Donnatal® and EnteraGam® in the U.S. GlobeNewswire
08:00AM  Concordia International Corp. Announces RedHill Biopharma Has Started Promoting Donnatal® in the U.S. CNW Group
Jun-06-17 07:00AM  RedHill Biopharma to Present at the 2017 BIO International Convention GlobeNewswire
May-04-17 08:00AM  RedHill Biopharma Announces Poster Presentation of the Positive RHB-105 Phase III Results for H. pylori Infection at Digestive Disease Week 2017 GlobeNewswire
May-03-17 06:02AM  RedHill Biopharma Reports 2017 First Quarter Financial Results GlobeNewswire
Apr-25-17 07:00AM  RedHill Biopharma to Host First Quarter 2017 Financial Results Conference Call on May 3, 2017 GlobeNewswire
Apr-24-17 07:01AM  RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D GlobeNewswire
Apr-20-17 07:00AM  RedHill Biopharma Announces Peer-Reviewed Publication of the Positive YELIVA® Phase I Study Results in Advanced Solid Tumors GlobeNewswire
Apr-19-17 07:00AM  RedHill Biopharma to Host R&D Day on BEKINDA® for Acute Gastroenteritis and IBS-D GlobeNewswire
Apr-18-17 08:01AM  RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA® GlobeNewswire
Apr-13-17 06:00AM  RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT® for Migraines in Luxembourg GlobeNewswire
Apr-05-17 11:22AM  Company News for April 05, 2017 Zacks
11:22AM  Company News for April 05, 2017
07:01AM  RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam® GlobeNewswire
07:01AM  RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam®
Apr-04-17 06:06AM  RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma GlobeNewswire
06:06AM  RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma
Mar-30-17 07:00AM  RedHill Biopharma to Present at BioCentury Future Leaders in the Biotech Industry Conference GlobeNewswire
Mar-22-17 07:00AM  RedHill Biopharma to Present at the 2017 MAP Conference GlobeNewswire
Mar-21-17 09:02AM  RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn's Disease GlobeNewswire
09:00AM  RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohns Disease GlobeNewswire
Mar-14-17 02:49PM  RedHill Biopharma Ltd. :RDHL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:49PM  RedHill Biopharma Ltd. :RDHL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-13-17 08:00AM  RedHill Biopharma to Present at the BIO-Europe Spring 2017 Conference GlobeNewswire
Mar-07-17 08:00AM  RedHill Biopharmas Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating to Donnatal® GlobeNewswire
Mar-01-17 01:04PM  REDHILL BIOPHARMA LTD. Financials
Feb-23-17 10:07AM  RedHill Biopharma Announces Availability of Its Annual Report on Form 20-F Through Its Website GlobeNewswire
07:15AM  RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results GlobeNewswire
07:00AM  RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results GlobeNewswire
Feb-21-17 08:02AM  RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis GlobeNewswire
08:00AM  RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis GlobeNewswire
Feb-16-17 07:00AM  RedHill Biopharma to Host Fourth Quarter and Full-Year 2016 Financial Results Conference Call on February 23, 2017 GlobeNewswire
Feb-13-17 08:02AM  RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis GlobeNewswire
08:00AM  RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis GlobeNewswire
Feb-08-17 09:30AM  The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
Feb-07-17 07:41AM  4 Drug Stocks that are Broker Favorites
Feb-06-17 08:00AM  RedHill Biopharma to Present at the BIO CEO & Investor Conference GlobeNewswire
Jan-25-17 09:30AM  The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
Jan-24-17 08:14AM  Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?
Jan-12-17 08:15AM  Blog Coverage Redhill Receives QIDP Fast-Track Designation from FDA for its Nontuberculous Mycobacteria Infections Combination Therapy Accesswire
06:03AM  RedHill Biopharma Provides 2017 Semi-Annual Business Update GlobeNewswire
06:01AM  RedHill Biopharma Provides 2017 Semi-Annual Business Update GlobeNewswire
Jan-11-17 08:01AM  RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections GlobeNewswire
08:00AM  RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections GlobeNewswire
Jan-10-17 08:02AM  RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection GlobeNewswire
08:00AM  RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection GlobeNewswire
Jan-09-17 09:00AM  RedHill Biopharmas RHB-105 Positive Phase III Study Results for H. pylori Infection Presented at the Innovations in Gastroenterology 2017 Symposium GlobeNewswire
06:03AM  RedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management GlobeNewswire
06:00AM  RedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management GlobeNewswire
Jan-06-17 08:01AM  RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference GlobeNewswire
08:00AM  RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference GlobeNewswire
Jan-05-17 07:00AM  RedHill Biopharma Announces New Research Collaboration with Aarhus University for Oncology Drug MESUPRON GlobeNewswire
Jan-04-17 08:15AM  Blog Coverage RedHill Biopharma Signs Co-Promotion Agreement with Concordia and Announces Exercise of Underwriters Options Accesswire
07:00AM  RedHill Biopharma to Present the Positive Results of the First Phase III study with RHB-105 for H. pylori Infection at the Innovations in Gastroenterology 2017 Symposium GlobeNewswire
Jan-03-17 11:10AM  RedHill Biopharma Announces Exercise of Underwriters' Option GlobeNewswire
11:02AM  RedHill Biopharma Announces Exercise of Underwriters Option GlobeNewswire
07:02AM  RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal® GlobeNewswire
07:00AM  RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal® GlobeNewswire
07:00AM  Concordia International Corp. Announces Co-Promote Agreement for Donnatal® CNW Group
Dec-28-16 07:00AM  RedHill Biopharma to Present at the Biotech Showcase 2017 GlobeNewswire
Dec-27-16 10:24AM  RedHill Biopharma Announces Closing of Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants and Partial Exercise of the Option of Underwriters GlobeNewswire
10:12AM  RedHill Biopharma Announces Closing of Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants and Partial Exercise of the Option of Underwriters GlobeNewswire
Dec-21-16 09:20AM  RedHill Biopharma Prices Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants GlobeNewswire -10.28%
Dec-20-16 04:03PM  RedHill Biopharma Announces Proposed Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants GlobeNewswire
04:01PM  RedHill Biopharma Announces Proposed Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants GlobeNewswire
Dec-19-16 08:02AM  RedHill Biopharma Announces First Patient Dosed in Phase Ib/II Study with YELIVA® for Multiple Myeloma GlobeNewswire
08:00AM  RedHill Biopharma Announces First Patient Dosed in Phase Ib/II Study with YELIVA® for Multiple Myeloma GlobeNewswire
Dec-14-16 11:50PM  S&W Seed Company (SANW): How Does It Stack Up Against Its Peers? at Insider Monkey
08:01AM  RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT® for Migraines with Pharmatronic Co. in South Korea GlobeNewswire
08:00AM  RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT® for Migraines with Pharmatronic Co. in South Korea GlobeNewswire
Dec-13-16 08:02AM  RedHill Biopharma Announces Positive and Unanimous DSMB Recommendation for Continuation of Phase III Study with RHB-104 for Crohn's Disease GlobeNewswire
RedHill Biopharma Ltd., an Israeli biopharmaceutical company, focuses on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. The company's pipeline of therapeutic candidates include RHB-105 intended for the eradication of Helicobacter pylori infection that is under Phase III study; RHB-104 for the treatment of Crohn's disease, which is under Phase III study; BEKINDA for the prevention of chemotherapy and radiotherapy induced nausea and vomiting, and gastroenteritis and gastritis that is under phase III study; and RHB-106 intended for the preparation and cleansing of the gastrointestinal tract. Its pipeline of therapeutic candidates also comprise MESUPRON, a urokinase-type plasminogen activator inhibitor targeting gastrointestinal and other solid tumor cancers that has completed Phase II-stage; RP101, a Hsp27 inhibitor for the treatment of pancreatic and other gastrointestinal cancers; RIZAPORT, an oral thin film formulation of rizatriptan for acute migraines; and RHB-101 for the treatment of hypertension, heart failure, and left ventricular dysfunction. The company was founded in 2009 and is based in Tel Aviv, Israel.
open in yahoo | open in reuters | open in google